



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 58857

**Title:** Chronic Myeloid Leukemia - From the Philadelphia chromosome to specific target drugs - a literature review

**Reviewer's code:** 00503536

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Brazil

**Manuscript submission date:** 2020-08-11

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2020-11-25 13:05

**Reviewer performed review:** 2020-11-29 03:42

**Review time:** 3 Days and 14 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

#### **SPECIFIC COMMENTS TO AUTHORS**

The review manuscript written by Sampaio MM et al. summarized the diagnosis, immunopathogenesis and new treatments of chronic myelogenous leukemia. The review is comprehensive and could give important information to the readers. However, there are some minor points that need to be addressed. Minor points, 1. In the section of DIAGNOSIS, more specific statements on the way to make the diagnosis of CML should be mentioned including cytogenetic and molecular tests. Are there any patients with negativity for both Ph chromosome and BCR-ABL gene? If so, how the diagnosis should be made? 2. In the section of immunobiology, the authors mention about increased Treg cells and abnormal activation of the PD-1/PD-L1 signaling. However, there is no description on immunotherapy in relation to the immunobiology. 3. The diagnosis, immunopathogenesis or treatment of the blast crisis should be mentioned.



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 58857

**Title:** Chronic Myeloid Leukemia - From the Philadelphia chromosome to specific target drugs - a literature review

**Reviewer's code:** 05445979

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Germany

**Author's Country/Territory:** Brazil

**Manuscript submission date:** 2020-08-11

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2020-11-24 13:41

**Reviewer performed review:** 2020-12-14 02:50

**Review time:** 19 Days and 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## SPECIFIC COMMENTS TO AUTHORS

In principle, gene names should always be written with capital letters and cursive. Example gene: BCR-ABL1; protein: BCR-ABL. In the gene nomenclature of BCR-ABL1, the 1 was often forgotten. If the protein is meant, then the 1 should be omitted. This form should be consistently maintained. Instead of CML, LMC was often written (3.2; 6.; 6.2; 6.3) 4.1: a sentence was started and not finished: "The leukocyte count can be as high as... ?" When quoting in sentences, be consistent. For example: Morris et al. ... The point was sometimes forgotten (4.3; 4.4; 4.6). 4.7: agnogenic myeloid metaplasia is mentioned. This is a historical term no longer in use and should be replaced by primary osteomyelofibrosis. 4.8: quantitative RT-PCR should be used instead of RQ-PCR. 4.8, third paragraph: FISH is proposed to be performed only when bone marrow cells cannot be obtained. On which interphases should FISH then be performed? 4.8, fourth paragraph: old ELN recommendations are discussed. In the new one by Hochhaus et al. 2020, no standard regular iliac crest puncture is recommended for cytogenetics, but rather quantitative RT-PCR (see reference no 144). 5.1, third paragraph: What is meant by GLA? Furthermore, in addition to pleural effusions, thrombocytopenias occur very frequently with dasatinib. 5.1, fifth paragraph: a space is missing between V299L and ABL kinase. 5.2, third sentence. Not half of CML patients die from their disease. 5.3: The third paragraph (OCT1 and ABCG2 etc) belongs to 5.4 (BCR-ABL-independent resistance) 5.4: When listing proteins, either write them all out or abbreviate them all (including Tpl2) and explain in a list of abbreviations. 5.6: Please also mention that there are already recruiting studies combining asciminib with other TKI (e.g. NCT03906292, NCT02081378, NCT03578367). 5.8: In heading Danusertib instead of Danustertibe. In the fourth sentence probably is meant allosteric instead of hysteric. In the fifth sentence are included 37 what? 5.13: Reference is made to a Table 1 that does



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

not exist. Second paragraph: Probably HSCT instead of TCHT. Probably BP instead of BF.

6.1, last sentence: a space is missing before „possibly"      6.3, second paragraph:  
Rather CD4+ T cells instead of TCD4. Instead of "decline in the BCR-ABL quantity"  
better decline of the BCR-ABL mRNA level (same in 6.4, second paragraph).



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 58857

**Title:** Chronic Myeloid Leukemia - From the Philadelphia chromosome to specific target drugs - a literature review

**Reviewer's code:** 05445979

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Germany

**Author's Country/Territory:** Brazil

**Manuscript submission date:** 2020-08-11

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2020-12-23 08:28

**Reviewer performed review:** 2020-12-23 08:58

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**https://**[www.wjgnet.com](http://www.wjgnet.com)

Dear Author. After your extensive and detailed revisions, I consider this article to be a complete review of CML disease, presenting the aspects of diagnosis and therapy at the current state of the art. Therefore, I would like to recommend the article to be accepted for publication.